Rapamycin as a preventive intervention for Alzheimer’s disease in APOE4 carriers:Targeting brain metabolic and vascular restoration  

作　　者：Ai-Ling Lin Chetan Aware 

机构地区：[1]Department of Radiology,University of Missouri,Columbia,MO,USA [2]NextGen Precision Health,University of Missouri,Columbia,MO,USA [3]Division of Biological Sciences,University of Missouri,Columbia,MO,USA [4]Institute for Data Science and Informatics,University of Missouri,Columbia,MO,USA

出　　处：《Neural Regeneration Research》2026年第2期685-686,共2页中国神经再生研究(英文版)

基　　金：supported by National Institute on Aging(NIH-NIA)R01AG054459(to ALL).

摘　　要：Alzheimer’s disease(AD)is the most common form of dementia,affecting over 50 million people worldwide.This figure is projected to nearly double every 20 years,reaching 82 million by 2030 and 152 million by 2050(Alzheimer’s Disease International).The apolipoproteinε4(APOE4)allele is the strongest genetic risk factor for late-onset AD(after age 65 years).Apolipoprotein E,a lipid transporter,exists in three variants:ε2,ε3,andε4.APOEε2(APOE2)is protective against AD,APOEε3(APOE3)is neutral,while APOE4 significantly increases the risk.Individuals with one copy of APOE4 have a 4-fold greater risk of developing AD,and those with two copies face an 8-fold risk compared to non-carriers.Even in cognitively normal individuals,APOE4 carriers exhibit brain metabolic and vascular deficits decades before amyloid-beta(Aβ)plaques and neurofibrillary tau tangles emerge-the hallmark pathologies of AD(Reiman et al.,2001,2005;Thambisetty et al.,2010).Notably,studies have demonstrated reduced glucose uptake,or hypometabolism,in brain regions vulnerable to AD in asymptomatic middle-aged APOE4 carriers,long before clinical symptoms arise(Reiman et al.,2001,2005).

关 键 词：lipid transporterexists Dementia alzheimer s disease ad RAPAMYCIN Brain metabolic Vascular restoration Amyloid beta plaques APOE 

分 类 号：R749.1[医药卫生—神经病学与精神病学]